Trial Condition(s):
Magnetic Resonance Imaging, Liver neoplasms
MRI study to evaluate 0.025 mmol/kg BW Gd-EOB-DTPA (SH L 569 B) and 0.05 mmol/kg BW Gd-BOPTA (Gadobenate Dimeglumine) in patients with known or suspected focal liver lesions
Bayer Identifier:
91106
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
298
Trial Dates
Phase
3
Could I receive a placebo?
No
Products
Eovist/Primovist (Gadoxetate disodium, BAY86-4873)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
Multicenter, double-blind, randomized, inter-individual comparison study in MRI with a corresponding blinded reading to evaluate 0.025 mmol/kg BW Gd-EOB-DTPA (SH L 569 B) and 0.05 mmol/kg BW Gd-BOPTA (gadobenate dimeglumine) after a single i.v. injection
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
